Regression of intestinal adenomas by vaccination with heat shock protein 105-pulsed bone marrow-derived dendritic cells in ApcMin/+ mice

Cancer Science

Volumn 98, Issue 12, 2007, Pages 1930-1935

  Yokomine, Kazunori ^a   Nakatsura, Tetsuya ^a,b   Senju, Satoru ^a   Nakagata, Naomi ^c   Minohara, Motozumi ^d   Kira, Jun Ichi ^d   Motomura, Yutaka ^a,b   Kubo, Tatsuko ^a   Sasaki, Yutaka ^a   Nishimura, Yasuharu ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; DENDRITIC CELL VACCINE; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 105; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; EMBRYO; FEMALE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMALL INTESTINE ADENOMA; SMALL INTESTINE TUMOR; TUMOR REGRESSION; WESTERN BLOTTING;

ADENOMA; ANIMALS; BONE MARROW CELLS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; GENE DELETION; GENES, APC; GENOTYPE; HSP110 HEAT-SHOCK PROTEINS; INTESTINAL NEOPLASMS; INTESTINAL POLYPS; MICE; MICE, INBRED C57BL;

EID: 35548994871     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00612.x     Document Type: Article

References (41)

1. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Büchler MW. Colorectal cancer. Lancet 2005; 365: 153-65.
2. Tournigand C, André T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004; 22: 229-37.
3. Rao CV, Cooma I, Rosa Rodriguez JG, Simi B, El-Bayoumy K, Reddy BS. Chemoprevention of familial adenomatous polyposis development in the Apc min mouse model by 1,4-phenylene bis (methylene)selenocyanate. Carcinogenesis 2000; 21: 617-21.
4. Kinzler KW, Vogelstein B. Cancer-susceptibility genes: Gatekeepers and caretakers. Nature 1997; 386: 761-3.
5. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-67.
6. Kikuchi A. Modulation of Wnt signaling by Axin and Axil. Cytokine Growth Factor Rev 1999; 10: 255-65.
7. Sancho E, Batlle E, Clevers H. Signaling pathways in intestinal development and cancer. Annu Rev Cell Dev Biol 2004; 20: 695-723.
8. Miyoshi Y, Ando H, Nagase H et al. Germ-line mutations of the APC gene in 53 familial adenomatous polyposis patients. Proc Natl Acad Sci USA 1992; 89: 4452-6.
9. Su LK, Kinzler KW, Vogelstein B et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 1992; 256: 668-70.
10. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990; 247: 322-4.
11. Feder ME, Hofmann GE. Heat-shock proteins, molecular chaperones, and the stress response: Evolutionary and ecological physiology. Annu Rev Physiol 1999; 61: 243-82.
12. Nakatsura T, Senju S, Yamada K, Jotsuka T, Ogawa M, Nishimura Y. Gene cloning of immunogenic antigens overexpressed in pancreatic cancer. Biochem Biophys Res Commun 2001; 281: 936-44.
13. Kai M, Nakatsura T, Egami H, Senju S, Nishimura Y, Ogawa M. Heat shock protein 105 is overexpressed in a variety of human tumors. Oncol Rep 2003; 10: 1777-82.
14. Yokomine K, Nakatsura T, Minohara M et al. Immunization with heat shock protein 105-pulsed dendritic cells leads to tumor rejection in mice. Biochem Biophys Res Commun 2006; 343: 269-78.
15. + T cells. Cancer Sci 2005; 96: 695-705.
16. Hosaka S, Nakatsura T, Tsukamoto H, Hatayama T, Baba H, Nishimura Y. Synthetic small interfering RNA targeting heat shock protein 105 induces apoptosis of various cancer cells both in vitro and in vivo. Cancer Sci 2006; 97: 623-32.
17. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: Chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 2002; 20: 395-425.
18. Manjili MH, Wang XY, Chen X et al. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice. J Immunol 2003; 171: 4054-61.
19. Wang XY, Chen X, Manjili MH, Repasky E, Henderson R, Subjeck JR. Targeted immunotherapy using reconstituted chaperone complexes of heat shock protein 110 and melanoma-associated antigen gp100. Cancer Res 2003; 63: 2553-60.
20. Dietrich WF, Lander ES, Smith JS et al. Genetic identification of Mom -1, a major modifier locus affecting Min -induced intestinal neoplasia in the mouse. Cell 1993; 75: 631-9.
21. Yamagishi N, Nishihori H, Ishihara K, Ohtsuka K, Hatayama T. Modulation of the chaperone activities of Hsc70/Hsp40 by Hsp105α and Hsp105β. Biochem Biophys Res Commun 2000; 272: 850-5.
22. Nakatsura T, Komori H, Kubo T et al. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reaction in mice. Clin Cancer Res 2004; 10: 8630-40.
23. Fearnhead NS, Wilding JL, Bodmer WF. Genetics of colorectal cancer: hereditary aspects and overview of colorectal tumorigenesis. Br Med Bull 2002; 64: 27-43.
24. Boivin GP, Washington K, Yang K et al. Pathology of mouse models of intestinal cancer: Consensus report and recommendations. Gastroenterology 2003; 124: 762-77.
25. Oshima M, Dinchuk JE, Kargman SL et al. Suppression of intestinal polyposis in Apc Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87: 803-9.
26. Reddy BS, Hirose Y, Lubet R et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 2000; 60: 293-7.
27. Steinbach G, Lynch PM, Philips RKS et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-52.
28. Solomon SD, McMurray JJV, Pfeffer MA et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071-80.
29. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 328-32.
30. Stift A, Friedl J, Dubsky P et al. Dendritic cell-based vaccination in solid cancer. J Clin Oncol 2003; 21: 135-42.
31. Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 2004; 64: 4973-9.
32. Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 1999; 50: 507-29.
33. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 2000; 18: 245-73.
34. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nature Rev Immunol 2004; 4: 941-52.
35. Park D, Lapteva N, Seethammagari M, Slawin KM, Spencer D. An essential role for Akt1 in dendritic cell function and tumor immunotherapy. Nat Biotechnol 2006; 24: 1581-90.
36. Evel-Kabler K, Song XT, Aldrich M, Huang XF, Chen SY. SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J Clin Invest 2006; 116: 90-100.
37. Hanks BA, Jiang J, Singh RAK et al. Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo. Nat Med 2005; 11: 130-7.
38. Reits EA, Hodge JW, Herberts CA et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006; 203: 1259-71.
39. Casares N, Pequignot MO, Tesniere A et al. Caspase-dependent immnogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202: 1691-701.
40. Zhang B, Bowerman NA, Salama JK et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med 2007; 204: 49-55.
41. + T lymphocytes. Nature 2003; 421: 852-6.